Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hemorrhage

ClinicalTrials.gov lists 4,992 trials for Hemorrhage or a narrower condition beneath it. Bayer has the most among industry and government lead sponsors, with 34.

MeSH D006470 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 182 Phase 1/2 Phase 1/2 95 Phase 2 Phase 2 474 Phase 2/3 Phase 2/3 91 Phase 3 Phase 3 558 Phase 4 Phase 4 513 Not applicable Not applicable 1,597 Observational Observational 1,475 Phase 1 Phase 1 182 Phase 1/2 Phase 1/2 95 Phase 2 Phase 2 474 Phase 2/3 Phase 2/3 91 Phase 3 Phase 3 558 Phase 4 Phase 4 513 Not applicable Not applicable 1,597 Observational Observational 1,475

Trials per phase

1 more section with rows

1,380 of the 4,992 trials are tagged with Hemorrhage itself; the rest are tagged with a narrower condition beneath it.

Get the Hemorrhage report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hemorrhage trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 14 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 343

1990: 1 trials (Observational 1) 1992: 1 trials (Not applicable 1) 1993: 2 trials (Observational 1, Phase 3 1) 1994: 2 trials (Observational 1, Phase 3 1) 1995: 1 trials (Observational 1) 1996: 2 trials (Observational 1, Not applicable 1) 1997: 5 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2/3 1) 1998: 3 trials (Observational 2, Phase 3 1) 1999: 6 trials (Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 2) 2000: 16 trials (Observational 4, Not applicable 3, Phase 4 3, Phase 3 1, Phase 2 5) 2001: 14 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 6) 2002: 28 trials (Observational 4, Not applicable 5, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 5, Phase 1/2 2) 2003: 35 trials (Observational 6, Not applicable 6, Phase 4 4, Phase 3 10, Phase 2/3 2, Phase 2 5, Phase 1/2 2) 2004: 49 trials (Observational 10, Not applicable 10, Phase 4 10, Phase 3 11, Phase 2 7, Phase 1 1) 2005: 74 trials (Observational 8, Not applicable 17, Phase 4 7, Phase 3 23, Phase 2/3 2, Phase 2 12, Phase 1/2 2, Phase 1 3) 2006: 91 trials (Observational 17, Not applicable 21, Phase 4 12, Phase 3 23, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 4) 2007: 98 trials (Observational 17, Not applicable 24, Phase 4 15, Phase 3 19, Phase 2/3 1, Phase 2 11, Phase 1/2 6, Phase 1 5) 2008: 119 trials (Observational 30, Not applicable 31, Phase 4 19, Phase 3 15, Phase 2/3 3, Phase 2 15, Phase 1/2 2, Phase 1 4) 2009: 121 trials (Observational 29, Not applicable 28, Phase 4 26, Phase 3 15, Phase 2/3 1, Phase 2 17, Phase 1/2 5) 2010: 162 trials (Observational 53, Not applicable 41, Phase 4 19, Phase 3 13, Phase 2/3 3, Phase 2 24, Phase 1 9) 2011: 157 trials (Observational 53, Not applicable 41, Phase 4 16, Phase 3 16, Phase 2/3 4, Phase 2 15, Phase 1/2 2, Phase 1 10) 2012: 187 trials (Observational 50, Not applicable 53, Phase 4 23, Phase 3 30, Phase 2/3 8, Phase 2 17, Phase 1/2 3, Phase 1 3) 2013: 212 trials (Observational 56, Not applicable 59, Phase 4 24, Phase 3 24, Phase 2/3 5, Phase 2 22, Phase 1/2 8, Phase 1 14) 2014: 220 trials (Observational 63, Not applicable 72, Phase 4 27, Phase 3 29, Phase 2/3 4, Phase 2 14, Phase 1/2 4, Phase 1 7) 2015: 222 trials (Observational 62, Not applicable 67, Phase 4 28, Phase 3 28, Phase 2/3 4, Phase 2 18, Phase 1/2 9, Phase 1 6) 2016: 223 trials (Observational 69, Not applicable 56, Phase 4 30, Phase 3 22, Phase 2/3 8, Phase 2 28, Phase 1/2 3, Phase 1 7) 2017: 215 trials (Observational 59, Not applicable 71, Phase 4 27, Phase 3 30, Phase 2/3 4, Phase 2 17, Phase 1 7) 2018: 264 trials (Observational 81, Not applicable 88, Phase 4 31, Phase 3 30, Phase 2/3 2, Phase 2 18, Phase 1/2 6, Phase 1 8) 2019: 273 trials (Observational 102, Not applicable 87, Phase 4 24, Phase 3 25, Phase 2/3 3, Phase 2 20, Phase 1/2 4, Phase 1 8) 2020: 274 trials (Observational 93, Not applicable 102, Phase 4 17, Phase 3 28, Phase 2 23, Phase 1/2 3, Phase 1 8) 2021: 292 trials (Observational 103, Not applicable 97, Phase 4 25, Phase 3 26, Phase 2/3 7, Phase 2 22, Phase 1/2 4, Phase 1 8) 2022: 299 trials (Observational 87, Not applicable 113, Phase 4 26, Phase 3 27, Phase 2/3 6, Phase 2 30, Phase 1/2 2, Phase 1 8) 2023: 299 trials (Observational 88, Not applicable 122, Phase 4 26, Phase 3 14, Phase 2/3 4, Phase 2 25, Phase 1/2 8, Phase 1 12) 2024: 331 trials (Observational 120, Not applicable 120, Phase 4 23, Phase 3 19, Phase 2/3 7, Phase 2 26, Phase 1/2 2, Phase 1 14) 2025: 343 trials (Observational 95, Not applicable 134, Phase 4 22, Phase 3 27, Phase 2/3 5, Phase 2 34, Phase 1/2 11, Phase 1 15)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 317
2025 343
2024 331
2023 299
2022 299
2021 292
2020 274
2019 273
2018 264
2017 215

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 370 trials starting in 2026 and about 360 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 463 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 2,811 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hemorrhage trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 182
Phase 1/2 95
Phase 2 474
Phase 2/3 91
Phase 3 558
Phase 4 513
Not applicable 1,597
Observational 1,475
Expanded access 7

How many Hemorrhage trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 305
Recruiting 630
Enrolling by invitation 32
Active, not recruiting 110
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hemorrhage trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Bayer 34
GlaxoSmithKline 25

Which drugs are being tested for Hemorrhage? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
MisoprostoL 79
Eltrombopag 53
Rivaroxaban 34
RITUXIMAB 33
Romiplostim 29

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
acid tranexamic 273
IM Oxytocin 106
carbetocin 100 µg 58
Dexamethasone/Dexamethasone acetate 47
EC Aspirin 38

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hemorrhage trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
SAE 660 1
Pneumonia 332 68
Direct effects of primary ICH event 297 1
Non-vasular injury (including fracture) 203 1
Thrombocytopenia 168 47

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hemorrhage? (3,768)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Catheter-based left atrial appendage CLOSURE in patients with atrial fibrillation at high risk of stroke and bleeding as compared to best medical therapy: Rationale and design of the prospective randomized CLOSURE-AF trial. American heart journal 2026 Yes
Early oral anticoagulation monotherapy after PCI: Insights from the POEM trial. American heart journal 2026 Yes
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. The New England journal of medicine 2026 Yes
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial. The Lancet. Haematology 2026 Yes
Blood transfusion strategies for major bleeding in trauma. The Cochrane database of systematic reviews 2025 Yes

Showing 5 of 3,768 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (20)

MeSH descendants one level down with at least one trial, most trials first.

+10 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages